National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
Topics
- Adverse Drug Events (ADE) (1)
- Adverse Events (1)
- Behavioral Health (1)
- Blood Thinners (1)
- Cancer (1)
- Cardiovascular Conditions (1)
- Comparative Effectiveness (1)
- Data (1)
- Depression (1)
- Evidence-Based Practice (1)
- Guidelines (1)
- (-) Medication (6)
- Medication: Safety (1)
- Outcomes (1)
- Patient Safety (1)
- Primary Care (1)
- (-) Research Methodologies (6)
- Risk (1)
- Stroke (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 6 of 6 Research Studies DisplayedShmuel S, Leonard CE, Bykov K
Breaking research silos and stimulating "innovation at the edges" in epidemiology.
The authors discuss the importance of promoting an exchange of ideas across seemingly disparate epidemiologic subdisciplines. This exchange could lead to opportunities to learn from and to merge knowledge across subdisciplines, as well as promote "innovation at the edges." The authors also outline specific steps to promote such innovation at the researcher, institution, and professional society level.
AHRQ-funded; HS027623.
Citation: Shmuel S, Leonard CE, Bykov K .
Breaking research silos and stimulating "innovation at the edges" in epidemiology.
Am J Epidemiol 2023 Feb 24;192(3):323-27. doi: 10.1093/aje/kwac192.
Keywords: Evidence-Based Practice, Research Methodologies, Medication
Desai RJ, Wyss R, Jin Y
Extension of disease risk score-based confounding adjustments for multiple outcomes of interest: an empirical evaluation.
Use of disease risk score (DRS)-based confounding adjustment when estimating treatment effects on multiple outcomes is not well studied. In this empirical cohort study, the investigators compared dabigatran initiators and warfarin initiators with respect to risks of ischemic stroke and major bleeding in 12 sequential monitoring periods (90 days each), using data from the Truven Marketscan database (Truven Health Analytics, Ann Arbor, Michigan).
AHRQ-funded; HS022193.
Citation: Desai RJ, Wyss R, Jin Y .
Extension of disease risk score-based confounding adjustments for multiple outcomes of interest: an empirical evaluation.
Am J Epidemiol 2018 Nov;187(11):2439-48. doi: 10.1093/aje/kwy130.
.
.
Keywords: Blood Thinners, Cardiovascular Conditions, Medication, Outcomes, Research Methodologies, Risk, Stroke
Wang SV, Maro JC, Baro E
Data mining for adverse drug events with a propensity score-matched tree-based scan statistic.
In this study, the investigators propose a method that combines tree-based scan statistics with propensity score-matched analysis of new initiator cohorts, a robust design for investigations of drug safety. They subsequently conducted plasmode simulations to evaluate performance. The authors suggest that TreeScan with propensity score matching shows promise as a method for screening and prioritization of potential adverse events.
AHRQ-funded; HS022193.
Citation: Wang SV, Maro JC, Baro E .
Data mining for adverse drug events with a propensity score-matched tree-based scan statistic.
Epidemiology 2018 Nov;29(6):895-903. doi: 10.1097/ede.0000000000000907..
Keywords: Adverse Drug Events (ADE), Adverse Events, Patient Safety, Medication, Medication: Safety, Data, Research Methodologies
Crossley JR, Tan TP, Smith KH
Review of clinical trial settings of drugs commonly used in primary care and approved between 2005 and 2012.
This study examined where clinical trial settings are conducted for drugs commonly used in primary care that were approved by the FDA between 2005 and 2012. The majority of clinical trials did not specify if the trials were conducted at a primary care facility or a specialist, however, of the principal investigators (PIs) the vast majority were specialty physicians. The authors believe that more adverse drug events would occur in clinical trials taking place at specialist offices due to more patients with comorbidities going there for treatment. An initiative called the FDA Drug Trials Snapshots was cited as a way to provide more demographic information of trial participants.
AHRQ-funded; HS022882.
Citation: Crossley JR, Tan TP, Smith KH .
Review of clinical trial settings of drugs commonly used in primary care and approved between 2005 and 2012.
J Gen Intern Med 2018 Sep;33(9):1431-32. doi: 10.1007/s11606-018-4486-7..
Keywords: Medication, Primary Care, Research Methodologies
Cosgrove L, Krimsky S, Wheeler EE
Conflict of interest policies and industry relationships of guideline development group members: A cross-sectional study of clinical practice guidelines for depression.
The purpose of the present study was to assess a) the disclosure requirements of guideline development groups in a cross-section of guidelines for major depression; and, b) the extent and type of conflicts of panel members. It found that most of the guidelines were developed by panels that had members with industry financial ties to drug companies that manufacture antidepressant medication.
AHRQ-funded; HS022940.
Citation: Cosgrove L, Krimsky S, Wheeler EE .
Conflict of interest policies and industry relationships of guideline development group members: A cross-sectional study of clinical practice guidelines for depression.
Account Res 2017;24(2):99-115. doi: 10.1080/08989621.2016.1251319.
.
.
Keywords: Medication, Depression, Guidelines, Behavioral Health, Research Methodologies
Wang WJ, Robertson JC, Basu A
Burden of illness and research investments in translational sciences for pharmaceuticals in metastatic cancers.
This study explored whether investments in translational sciences for six metastatic cancers follow idiosyncratic returns to those investments rather than levels of burden of illness (BI). It concluded that investments in trials were positively associated only with contemporary changes in BI (2008-2014). The relationship was stronger for government-sponsored comparative-effectiveness trials than for industry.
AHRQ-funded; HS022982.
Citation: Wang WJ, Robertson JC, Basu A .
Burden of illness and research investments in translational sciences for pharmaceuticals in metastatic cancers.
J Comp Eff Res 2017 Jan;6(1):15-24. doi: 10.2217/cer-2016-0021.
.
.
Keywords: Cancer, Comparative Effectiveness, Medication, Research Methodologies